David A. Siegel Uni Qure N.V. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Uni Qure N.V. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 746,500 shares of QURE stock, worth $13 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
746,500
Previous 214,700
247.69%
Holding current value
$13 Million
Previous $961,000
282.93%
% of portfolio
0.01%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding QURE
# of Institutions
154Shares Held
41MCall Options Held
925KPut Options Held
617K-
Vestal Point Capital, LP New York, NY4.75MShares$82.4 Million1.78% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.78MShares$48.3 Million0.81% of portfolio
-
Boxer Capital, LLC San Diego, CA2.23MShares$38.6 Million0.58% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.19MShares$38 Million0.01% of portfolio
-
Abrdn PLC1.93MShares$33.5 Million0.02% of portfolio
About uniQure N.V.
- Ticker QURE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,729,100
- Market Cap $811M
- Description
- uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...